Weekly News Round-up – 17/4/20


This week, a glimpse of non-Covid normalcy is provided by news that a Tagrisso lung cancer study was unblinded early after ‘overwhelming accuracy’, potentially expanding the drug’s usage further. In other (Covid-related) news, GSK and Sanofi are set to collaborate on a treatment, Remdesivir trials have slowed in China over lack of enrolment, and Astrazeneca and Lilly are the latest companies to move into the coronavirus treatment space.
GSK AND SANOFI IN ‘UNPRECEDENTED’ COLLABORATION TO DEVELOP COVID-19 VACCINE – GSK and Sanofi will work together to develop a Covid-19 vaccine in what has been called an ‘unprecedented’ collaboration. If successful, the two companies could produce hundreds of millions of vaccines between them. The vaccine being developed is based on an existing DNA-based technology used to make Sanofi’s flu vaccine. GSK is contributing an adjuvant which triggers a stronger immune reaction. This adjuvant could lower necessary dose per person by a factor of four. This in turn would increase speed of production.
SECOND TRIAL OF REMDESIVIR STOPPED IN CHINA OVER PATIENT ENROLMENT – Two Remdesivir trials in China have been halted due to low patient enrolment. The studies, aimed at patients with milder Covid symptoms, failed after the number of cases dropped dramatically in the country over the last few weeks. Results published this week showed that while anecdotally patients recovered with the drug’s help, no concrete evidence was at hand. In the first study, 68% of patients showed clinical improvement after 10 days’ treatment. Limitations in the study, however, make the findings “impossible to interpret”.
AZ’S LUNG CANCER DRUG TAGRISSO UNBLINDED AFTER ‘OVERWHELMING’ EFFICACY – A study of Astrazeneca’s lung cancer drug Tagrisso will be unblinded due to high success. The Independent Data Monitoring Committee noted ‘overwhelming efficacy’. This is the first global trial of an EGFR inhibitor showing significant benefit in adjuvant treatment of lung cancer. It could significantly expand use of Tagrisso, which already has approval in 80 countries for first-line EGFRm advanced NSCLC.
In other news:
R&D
AZ and Lilly move into Covid-19 cure space with repurposed drugs
Clinical Trials
AZ testing Calquence on severe Covid-19 patients to treat exaggerated immune response
FDA receives FDA approval for combo colon cancer drug Braftovi
Manufacturing
UK experiences local shortages of anaesthetic medicines and painkillers
That’s all for now. See you next week!
Joshua Neil, Editor
Proventa International
To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Clinical Operations, Supply Chain & Pharmacovigilance Strategy Meeting 2020.

RNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years agoRNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years ago
Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years ago
Intrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets
Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...
2 years agoIntrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets
Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...
2 years ago